Hero image with Pittsburgh background pittplusme.org/study/2022

We're sorry. This study is closed and no longer recruiting participants.

STUDY BASICS

Do you have Primary Biliary Cholangitis (PBC)? You may be able to participate in a study to find out how safe and effective an investigational drug called elafibranor is for patients with PBC. The main part of the study lasts up to 2 years, but total participation can last up to 6 years. Compensation and reimbursement are provided.


IRB: 20200353
- A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid

PHONE NUMBER: 1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In

INTERESTED?

Visit pittplusme.org/study/2022 and click on "I'm Interested" or call 1-866-438-8230.


LEARN MORE

PittPlusMe.org
1-866-438-8230
PittPlusMe@pitt.edu
@PittPlusMe
@PittPlusMe

MEET THE RESEARCHER


Mordechai Rabinovitz

Mordechai Rabinovitz, MD, is a Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh. A graduate of Tel-Aviv University in Israel, Dr. Rabinovitz’s research interests include assessment and treatment of chronic viral hepatitis as well as developing new therapies for non-alcoholic fatty liver disease.